The Company identifies and sources innovative therapeutic drug candidates globally, and develops these drug candidates in accordance to the United States Food and Drug Administration regulatory standards to feed the product development pipelines of the pharmaceuticals industry.
The Company’s lead product, PAC-113, is an anti-fungal in a Phase II program for the treatment of oral Candidiasis. Pacgen recently reported positive efficacy results from its Phase IIb dose-ranging clinical trial of PAC-113. Pacgen also has an early stage research program. The most advanced candidate is a peptide therapeutic, PAC-G31P, which is being investigated in preclinical studies for its potential to treat inflammatory disease.
July 30, 2010
Pacgen Reports Fiscal 2010 Financial Results
June 8, 2010
Pacgen Completes Share Consolidation
May 28, 2010
Pacgen Closes Private Placement Financing
April 19, 2010
Pacgen Announces Private Placement Financing and Financial Restructuring